Yeon Soo Kim

Prof. Yeon Soo Kim


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2013 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
YKYeon Soo Kim
Yeon Soo Kim

28 February 2023 in Clinical and Experimental Otorhinolaryngology
Verified
Journal Article
Open access
PDF file
JPJun-Ook Park
Jun-Ook Park
JKJOO HYUN KIM
JOO HYUN KIM
YJYoung Hoon Joo
Young Hoon Joo
SKSang-Yeon Kim
Sang-Yeon Kim
GKGeun-Jeon Kim
Geun-Jeon Kim
SKSoon-Young Kwon
Soon-Young Kwon
The aim of this study was to develop evidence-based recommendations for determining the surgical extent in patients with locally invasive differentiated thyroid cancer (DTC). Locally invasive DTC with gross extrathyroidal extension invading surrounding anatomical structures may lead to several functional deficits and poor oncological outcomes. At present, the optimal extent of surgery in locally invasive DTC remains a matter of debate, and there are no adequate guidelines. On October 8, 2021, four experts searched the PubMed, Embase, and Cochrane Library databases; the identified papers were reviewed by 39 experts in thyroid and head and neck surgery. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the quality of evidence, and to develop and report recommendations. The strength of a recommendation reflects the confidence of a guideline panel that the desirable effects of an intervention outweigh any undesirable effects, across all patients for whom the recommendation is applicable. After completing the draft guidelines, Delphi questionnaires were completed by members of the Korean Society of Head and Neck Surgery. Twenty-seven evidence-based recommendations were made for several factors, including the preoperative workup; surgical extent of thyroidectomy; surgery for cancer invading the strap muscles, recurrent laryngeal nerve, laryngeal framework, trachea, or esophagus; and surgery for patients with central and lateral cervical lymph node involvement. Evidence-based guidelines were devised to help clinicians make safer and more efficient clinical decisions for the optimal surgical treatment of patients with locally invasive DTC.

16 November 2024 in Biomimetics
Verified
Journal Article
Open access
PDF file
YKYeon Soo Kim
Yeon Soo Kim
YSYoo Seob Shin
Yoo Seob Shin
Three-dimensional (3D) printing is a highly effective scaffold manufacturing technique that may revolutionize tissue engineering and regenerative medicine. The use of scaffolds, along with growth factors and cells, remains among the most promising approaches to organ regeneration. However, the applications of hard 3D-printed scaffolds may be limited by their poor surface properties, which play a crucial role in cell recruitment and infiltration, tissue–scaffold integration, and anti-inflammatory properties. However, various prerequisites must be met before 3D-printed scaffolds can be applied clinically to the human body. Consequently, various attempts have been made to modify the surfaces, porosities, and mechanical properties of these scaffolds. Techniques that involve the chemical and material modification of surfaces can also be applied to enhance scaffold efficacy. This review summarizes the characteristics and discusses the developmental directions of the latest 3D-printing technologies according to its intended application in unmet clinical needs.

1 May 2021 in Clinical and Experimental Otorhinolaryngology
Verified
Journal Article
Open access
PDF file
JPJun-Ook Park
Jun-Ook Park
영M영민 young min
영민 young min
WJWoo-Jin Jeong
Woo-Jin Jeong
YSYooseob Shin
Yooseob Shin
YHYong Tae Hong
Yong Tae Hong
SBSeung-Kuk Baek
Seung-Kuk Baek
Objectives. Head and neck squamous cell carcinomas (HNSCs) are frequently diagnosed at the locoregional advanced stage (stage IVa), but controversy remains regarding whether stage IVa HSNCs should be treated with upfront surgery or definitive chemoradiation therapy (CRT). The purpose of this study was to compare overall survival (OS) and disease-free survival (DFS) in patients with stage IVa HNSC treated primarily by surgery with curative intent with/without (neo)adjuvant treatment (surgery group) versus those treated primarily with CRT (CRT group).Methods. We reviewed data of 1,033 patients with stage IVa HNSC treated with curative intent at 17 cancer centers between 2010 and 2016.Results. Among 1,033 patients, 765 (74.1%) received upfront surgery and 268 (25.9%) received CRT. The 5-year OS and DFS rates were 64.4% and 62.0% in the surgery group and 49.5% and 45.4% in the CRT group, respectively. In multivariate analyses, OS and DFS were better in the surgery group than in the CRT group (odds ratio [OR] for death, 0.762; 95% confidence interval [CI], 0.592–0.981; OR for recurrence, 0.628; 95% CI, 0.492–0.802). In subgroup analyses, the OS and DFS of patients with oropharyngeal cancer were better in the surgery group (OR for death, 0.548; 95% CI, 0.341–0.879; OR for recurrence, 0.598; 95% CI, 0.377–0.948). In the surgery group, patients with laryngeal cancer showed better OS (OR for death, 0.432; 95% CI, 0.211–0.882), while those with hypopharyngeal cancer DFS was improved (OR for recurrence, 0.506; 95% CI, 0.328–0.780).Conclusion. A survival benefit from surgery may be achieved even in patients with stage IVa HNSC, particularly those with oropharyngeal and laryngeal cancer. Surgery led to a reduction in the recurrence rate in patients with hypopharyngeal cancer.

28 February 2025 in Clinical and Experimental Otorhinolaryngology
Verified
Journal Article
Open access
PDF file
KWKen Woo
Ken Woo
YKYeon Soo Kim
Yeon Soo Kim
CACeline Abueva
Celine Abueva
SWSeung Hoon Woo
Seung Hoon Woo
Photobiomodulation (PBM), a noninvasive phototherapy that utilizes wavelengths between red and near-infrared light, has emerged as a promising approach for controlling inflammation by modulating macrophage polarization. This review investigates the therapeutic potential of PBM in treating ENT-specific inflammatory conditions, such as chronic rhinosinusitis and otitis media, focusing on its effects on macrophage phenotypes and evidence from preclinical studies. By promoting mitochondrial activity, increasing adenosine triphosphate production, and modulating reactive oxygen species, PBM has been shown to shift macrophages from a pro-inflammatory to an anti-inflammatory phenotype. Studies have demonstrated that PBM enhances tissue repair, reduces inflammatory markers, and promotes wound healing. Moreover, PBM facilitates the polarization of M2 macrophages, a crucial factor in resolving mucosal inflammation in the nasal, pharyngeal, and middle ear cavities, as well as restoring tissue homeostasis. The anti-inflammatory effects of PBM are attributed to its ability to influence several molecular mechanisms involved in inflammation regulation, particularly in ENT organ tissues, where recurrent inflammation can lead to chronic conditions such as otitis media or sinusitis. Furthermore, this review compares PBM to competing methods for reprogramming macrophages and treating inflammation, highlighting its advantages of minimal toxicity, simplicity, and precision in controlling ENT immune responses.

17 December 2022 in Experimental Biology and Medicine
Verified
Journal Article
Closed access
SLSunYoung Lee
SunYoung Lee
SPSunjung Park
Sunjung Park
JRJae-Sung Ryu
Jae-Sung Ryu
JKJaegu Kang
Jaegu Kang
IKIkhee Kim
Ikhee Kim
YKYeon Soo Kim
Yeon Soo Kim
Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancer, causing considerable mortality and morbidity worldwide. Although HNSCC management has been extensively studied, the treatment outcomes have not improved – the 5-year survival rate of patients with HNSCC is 40%. Recent studies on the development of a novel HNSCC treatment have highlighted proto-oncogene tyrosine-protein kinase Src (c-Src) as one of the major therapeutic targets. However, the clinical efficacy of c-Src inhibitors against HNSCC was not comparable to that obtained in vitro. Furthermore, the molecular mechanisms underlying the efficacy of c-Src inhibitors remain elusive. In this study, we assessed the efficacy of 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d] pyrimidine (PP2), a selective c-Src inhibitor on HSNCC. Nine HNSCC cell lines (SNU1041, Fraud, SNU46, SNU1076, SNU899, SCC1483, YD15, YD9, and YD10-) were screened, and the effects of PP2 were evaluated using wound healing, apoptosis, and invasion assays. Western blot analysis of downstream markers was conducted to assess the specific mechanism of action of PP2 in HNSCC. The therapeutic efficacy of PP2 was further evaluated in xenograft mice. PP2 reduced tumor cell growth both in vitro and in vivo. Furthermore, it enhanced tumor cell apoptosis in cell lines and prevented metastasis in mice. PP2 also regulated the epithelial–mesenchymal transition pathway downstream of c-Src. More specifically, in SCC1483 and YD15PP2 HNSCC cell lines, PP2 exposure downregulated Erk, Akt/Slug, and Snail but upregulated E-cadherin. These results suggest that PP2 inhibits cell growth and progression in HNSCC by regulating the epithelial–mesenchymal transition pathway.